眼弓形体病伴脉络膜新生血管患者玻璃体内注射雷珠单抗后玻璃体黄斑牵引的缓解。
Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization.
机构信息
Moorfields Eye Hospital, London, UK ; Ophthalmology Department, University of Athens, Athens, Greece.
出版信息
Ther Clin Risk Manag. 2013;9:391-4. doi: 10.2147/TCRM.S52161. Epub 2013 Oct 18.
PURPOSE
To present the occurrence of the resolution of vitreomacular traction following intravitreal ranibizumab in two patients with inflammatory choroidal neovascular (CNV) membrane with a background of ocular toxoplasmosis.
METHODS
Interventional case report.
RESULTS
A 21-year-old Caucasian woman and a 52-year-old Caucasian man both presented with vitreomacular traction with coexistent classic CNV membrane and a background of ocular toxoplasmosis. They both received an intravitreal injection of ranibizumab in an effort to control the underlying CNV membrane. A resolution of the vitreomacular traction was observed within 1 week of the intravitreal injection in both cases.
CONCLUSION
To the best of our knowledge, this is the first reported case of vitreomacular traction resolution in two patients with ocular toxoplasmosis following ranibizumab administration. Of course, further studies are needed in order to adequately support this association.
目的
介绍 2 例眼弓蛔虫病背景下的炎症性脉络膜新生血管（CNV）膜患者玻璃体黄斑牵引在玻璃体内雷珠单抗治疗后的缓解情况。
方法
介入性病例报告。
结果
1 例 21 岁的白人女性和 1 例 52 岁的白人男性均表现为玻璃体黄斑牵引，同时存在典型的 CNV 膜和眼弓蛔虫病。他们均接受了玻璃体内雷珠单抗注射，以控制潜在的 CNV 膜。在玻璃体内注射后 1 周内，这两例患者的玻璃体黄斑牵引均得到缓解。
结论
据我们所知，这是首例报道的眼弓蛔虫病患者在玻璃体内注射雷珠单抗后玻璃体黄斑牵引缓解的病例。当然，还需要进一步的研究来充分支持这种关联。
Zotero 插件